Compare PRSU & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRSU | CGEM |
|---|---|---|
| Founded | 1926 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 946.6M | 780.4M |
| IPO Year | N/A | 2020 |
| Metric | PRSU | CGEM |
|---|---|---|
| Price | $36.60 | $13.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | ★ $31.67 | $30.11 |
| AVG Volume (30 Days) | 208.9K | ★ 752.7K |
| Earning Date | 05-07-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.85 | N/A |
| Revenue Next Year | $4.94 | N/A |
| P/E Ratio | $3.45 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $26.90 | $5.68 |
| 52 Week High | $38.71 | $16.74 |
| Indicator | PRSU | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 50.78 | 43.41 |
| Support Level | $32.56 | $11.43 |
| Resistance Level | $37.75 | $13.21 |
| Average True Range (ATR) | 1.22 | 0.94 |
| MACD | -0.06 | -0.36 |
| Stochastic Oscillator | 72.87 | 1.08 |
Pursuit Attractions and Hospitality Inc is an attractions and hospitality company that owns and operates a collection of inspiring and unforgettable experiences at iconic destinations across the United States, Canada, and Iceland. Its elevated hospitality offerings include point-of-interest attractions and distinctive lodges, as well as integrated restaurants, retail options, and transportation that allow visitors to discover and connect with breathtaking national parks and renowned travel locations.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.